中國光大控股(00165.HK)“17光控01”回售登記期6月10日開始
格隆匯6月11日丨中國光大控股(00165.HK)公佈,根據《中國光大控股有限公司2017年公開發行公司債券募集説明書(第一期)》,中國光大控股有限公司2017年公開發行公司債券(第一期)(品種一)的投資者有權選擇在投資者回售登記期內進行登記,將持有的本期債券按面值全部或部分回售給發行人;或選擇繼續持有本期債券。
回售登記期2020年6月10日至2020年6月16日。回售部分債券享有2017年7月10日至2020年7月9日期間利息,票面年利率為4.55%。付息每手債券面值1,000元的“17光控01”派發利息為人民幣45.50元(含税)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.